课题基金 / 基金详情

SAFETY AND EFFICACY OF HYDROXYUREA AS A PROPHYLACTIC THERAPY FOR SICKLE CELL

SAFETY AND EFFICACY OF HYDROXYUREA AS A PROPHYLACTIC THERAPY FOR SICKLE CELL
羟基脲作为镰状细胞预防疗法的安全性和有效性
批准号：
5217839
负责人：
Eugene P Orringer
金额：
$0.0万
依托单位：
--
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/5217839
关键词：
blood disorder chemotherapy clinical research clinical trials drug screening /evaluation erythrocytes hemoglobin F human subject human therapy evaluation hydroxyurea sickle cell anemia

项目摘要

项目成果

Eugene P Orringer的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of this double-blind, randomized study is: a) to compare the clinical course of patients receiving hydroxyurea to a control group receiving placebo and; b) to quantitate the effect of hydroxyurea on fetal hemoglobin production in the red blood cells of patients with sickle cell anemia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PERMEABILITY & METABOLISM OF RBC FROM PATIENTS WITH HEMOLYTIC ANEMIAS
CLINICAL TRIAL: NEUROPSYCHOLOGICAL DYSFUNCTION AND NEUROIMAGING ABNORMALITIES IN
NEUROPSYCHOLOGICAL DYSFUNCTION AND NEUROIMAGING ABNORMALITIES IN SCD
PERMEABILITY & METABOLISM OF RBC FROM PATIENTS WITH HEMOLYTIC ANEMIAS
海外基金